Imagine you are sitting in a doctor's office. You have just found out you are pregnant. You also have an autoimmune disease like rheumatoid arthritis or lupus. The fear hits hard. You wonder if your medications will hurt the baby. Many women feel this exact panic. For years, doctors told patients to stop all drugs before trying to conceive. That advice is outdated. In fact, stopping medication can be far more dangerous than continuing it.
The landscape of treating autoimmune diseases during pregnancy has changed dramatically. New guidelines from major medical organizations now support staying on treatment for most patients. This shift saves pregnancies and keeps mothers healthy. Understanding which drugs are safe and how to plan ahead is crucial. This guide breaks down the latest evidence so you can make informed choices with your care team.
Why Active Disease Is More Dangerous Than Most Drugs
You might think that any chemical in your body during pregnancy is risky. That is a common myth. The real danger comes from uncontrolled inflammation. When your immune system attacks your own body, it creates stress everywhere. This stress affects the placenta and the developing fetus.
Research shows that active disease poses greater risks than most medications. According to data reviewed by the American College of Obstetricians and Gynecologists (ACOG), 63% of patients who stop tumor necrosis factor (TNF) inhibitors at conception experience disease flares. Only 20% flare up if they continue therapy. A flare isn't just painful for you. It increases the risk of preterm birth, low birth weight, and preeclampsia. Dr. Megan Clowse, a leading expert in this field, notes that uncontrolled lupus carries three to five times higher risk of preeclampsia compared to well-controlled disease. Keeping your disease quiet is the best thing you can do for your baby.
The New Standard: EULAR Guidelines and Safety Data
In February 2025, the European Alliance of Associations for Rheumatology (EULAR) released updated guidance. This document reviewed over 1,200 clinical studies. The key finding? 87% of standard autoimmune treatments can be safely continued during conception, pregnancy, and breastfeeding. This is a massive shift from the conservative "stop everything" approach of the past.
Let’s look at specific drugs. Hydroxychloroquine is considered very safe. Studies covering over 12,000 pregnancies show a 98.7% safety profile with no increased risk of major birth defects. Azathioprine is another common option. It has a 95.3% safety rate across nearly 6,000 documented pregnancies. Sulfasalazine also maintains a high safety rating at 97.1%. These numbers give patients and doctors confidence. They prove that managing symptoms doesn't mean sacrificing fetal health.
| Medication | Safety Rating | Key Risk/Note |
|---|---|---|
| Hydroxychloroquine | 98.7% | No increased risk of congenital anomalies |
| Azathioprine | 95.3% | Low risk; slightly higher preterm birth risk vs. general population but lower than active disease |
| Sulfasalazine | 97.1% | No teratogenicity; requires folate supplementation |
| Certolizumab Pegol | High | Minimal placental transfer (0.2%); preferred biologic in 3rd trimester |
| Methotrexate | Contraindicated | 17.8% risk of major congenital anomalies; must stop 3 months prior |
| Mycophenolate Mofetil | Contraindicated | 24.4% risk of congenital anomalies; must stop 6 weeks prior |
Biologics: Choosing the Right One for Your Timeline
If you take biologics, timing matters. Not all biologics cross the placenta equally. TNF inhibitors as a group show a 94.8% safety rate across nearly 29,000 pregnancies. However, some transfer to the baby more than others. Certolizumab pegol stands out because it lacks a fragment crystallizable (Fc) region. This means it does not bind to receptors on the placenta. As a result, only 0.2% of the drug reaches the baby. Compare that to adalimumab, where 15.7% crosses over, or infliximab, where 23.4% transfers.
Because of this difference, many specialists prefer certolizumab pegol for use throughout pregnancy, especially in the third trimester. If you are on adalimumab or etanercept, your doctor might suggest pausing them after 30 weeks gestation. This reduces the amount of drug in the baby’s system at birth. Importantly, experts like Dr. Kristina Mahan note there is zero evidence that continuing these drugs past 32 weeks increases infection risk in newborns. The neonatal infection rates remain identical to unexposed infants. So, while switching or pausing is an option, it is not always mandatory if your disease is unstable.
Drugs to Avoid and the Washout Period
Some medications are strictly forbidden during pregnancy. Methotrexate and mycophenolate mofetil carry high risks of severe birth defects. Methotrexate is linked to a 17.8% risk of major congenital anomalies, including craniofacial and limb defects. Mycophenolate has a 24.4% risk, often affecting ears and eyes. If you are taking these, you cannot simply stop them the day you find out you are pregnant. You need a washout period.
EULAR guidelines recommend switching to safer alternatives at least three to six months before conception. Methotrexate stays in your system for a while, so you need a minimum three-month break. Mycophenolate requires at least six weeks. Planning this switch early prevents accidental exposure. This is why preconception counseling is vital. Don’t wait until you see a positive test. Start the conversation when you start trying.
The Role of Preconception Counseling
Preparation makes all the difference. Women who receive joint counseling from both a rheumatologist and a maternal-fetal medicine specialist have better outcomes. A survey by the Lupus Foundation of America found that these patients had a 53% lower rate of unplanned medication discontinuation. They also had a 37% higher rate of live births at term. This coordination ensures everyone is on the same page.
Your care team should include:
- A rheumatologist to manage your disease activity
- A maternal-fetal medicine specialist to monitor the pregnancy
- A pharmacist to review drug interactions and safety profiles
This multidisciplinary approach reduces anxiety. Many women report significant stress about medication safety. In one registry study, 68.3% of women felt anxious, and 41.7% stopped meds without asking their doctor. Having a clear plan written down helps you stick to it. It removes guesswork and fear.
Breastfeeding and Postpartum Considerations
Pregnancy doesn’t end at delivery. You may want to breastfeed. The good news is that most biologics are compatible with breastfeeding. About 98.4% of biologics have negligible transfer into breast milk. Adalimumab, for example, is detected in only 0.005-0.13% of maternal serum concentration in most samples. This tiny amount is unlikely to affect the baby. Corticosteroids like prednisone are also generally safe in moderate doses. Always discuss your postpartum medication plan before giving birth. Flares are common after delivery due to hormonal shifts. Being prepared helps you maintain your health while nurturing your newborn.
Future Directions and Emerging Treatments
Science is moving fast. There are still gaps in knowledge for newer drugs like JAK inhibitors. EULAR currently recommends avoiding them due to limited data, though some other guidelines are more lenient. The NIH launched a $12.7 million research network in January 2024 to study these drugs in pregnant patients. We expect clearer answers within the next few years. Meanwhile, personalized risk tools are being developed. Dr. Clowse’s team created a prediction tool that calculates individual flare risk based on 12 clinical factors. It has 87.3% accuracy. Soon, doctors might use these tools to tailor plans even more precisely to your unique biology.
Can I stay on hydroxychloroquine during pregnancy?
Yes. Hydroxychloroquine is considered very safe with a 98.7% safety profile. It reduces the risk of lupus flares and preeclampsia. Most experts recommend continuing it throughout pregnancy and breastfeeding.
Which biologic is safest in the third trimester?
Certolizumab pegol is often preferred because it has minimal placental transfer (only 0.2%). Other TNF inhibitors like adalimumab cross the placenta more significantly, so some doctors pause them after 30 weeks, though continuing them is also supported by recent safety data.
How long before pregnancy should I stop methotrexate?
You should stop methotrexate at least three months before conceiving. This allows enough time for the drug to clear your system and reduces the risk of birth defects. Switch to a pregnancy-safe alternative like azathioprine under medical supervision.
Is it better to stop all meds or keep taking them?
For most patients, keeping disease activity low is safer than stopping meds. Uncontrolled inflammation increases risks of preterm birth and preeclampsia. About 87% of standard treatments are safe to continue. Always consult your rheumatologist to choose the right balance for your specific condition.
Can I breastfeed while on biologics?
Yes, most biologics are compatible with breastfeeding. They transfer into breast milk in negligible amounts (often less than 0.13%). The benefits of breastfeeding usually outweigh the minimal exposure risk. Discuss your specific drug with your doctor to confirm.
